USMLE Step 1 general pathology questions

Plasma membrane rupture with extrusion of cellular contents, along with amorphous densities (calcium phosphate precipitates) in mitochondria and large myelin figures, are hallmark ultrastructural features of irreversible cell injury. Once the plasma membrane is physically disrupted, intracellular enzymes and calcium leak in uncontrolled fashion and the cell cannot recover even if blood flow is restored. Reversible injury, by contrast, is limited to cytoplasmic/mitochondrial swelling, blebbing, and ribosomal detachment, all of which can resolve if the stress is removed. The presence of membrane breaks is the defining morphologic point of no return.

• A. Ribosomal detachment causing decreased protein synthesis is a reversible change seen earlier in injury.
• B. Membrane blebbing without rupture is a reversible finding that precedes irreversible injury.
• C. Cytoplasmic swelling alone is a feature of reversible injury, not the membrane rupture described here.
• D. Isolated mitochondrial swelling without membrane rupture is still considered reversible.

ATP is required to power the Na+/K+-ATPase pump, which normally extrudes sodium and imports potassium against their concentration gradients. When ATP falls during hypoxia, pump activity decreases directly, causing intracellular accumulation of sodium and water influx, producing cellular and organelle swelling (cloudy swelling). This is one of the earliest and most consistent morphologic changes in reversible hypoxic injury. The subsequent failure of calcium pumps leads to increased, not decreased, cytosolic calcium, which activates damaging enzymes.

• A. ATP depletion activates glycolysis and depletes glycogen stores, so glycogen synthesis decreases.
• C. Oxidative phosphorylation decreases because oxygen delivery is interrupted, which is the cause of the ATP depletion.
• D. ATP depletion impairs calcium efflux pumps, raising, not lowering, intracellular calcium.
• E. Hypoxia impairs oxidative phosphorylation and electron transport, decreasing cytochrome c oxidase activity rather than increasing it.

Superoxide dismutase converts superoxide anion (O2•-) into hydrogen peroxide (H2O2) and molecular oxygen, representing the first line of defense against oxygen free radicals generated during oxidative stress. The resulting hydrogen peroxide is then detoxified into water and oxygen by catalase in peroxisomes or converted to water by glutathione peroxidase using reduced glutathione in the cytosol and mitochondria. NADPH oxidase and myeloperoxidase, in contrast, are enzymes that generate reactive oxygen species (in phagocytes) rather than neutralize them. Understanding this sequential detoxification pathway clarifies how cells limit oxidative injury after reperfusion.

• A. Glutathione peroxidase also acts on hydrogen peroxide (and lipid peroxides), not directly on superoxide.
• C. Myeloperoxidase in neutrophil lysosomes generates hypochlorite from hydrogen peroxide and chloride, contributing to microbial killing rather than neutralizing superoxide.
• D. NADPH oxidase generates superoxide from oxygen during the respiratory burst; it does not neutralize free radicals.
• E. Catalase acts downstream, converting hydrogen peroxide to water and oxygen, not superoxide to hydrogen peroxide.

Acetaminophen is normally metabolized mostly by glucuronidation and sulfation, but a small fraction is oxidized by cytochrome P450 2E1 to the toxic reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI), which is normally detoxified by conjugation with glutathione. In overdose, glutathione stores become depleted, allowing NAPQI to accumulate and covalently bind hepatocyte macromolecules, causing centrilobular necrosis. N-acetylcysteine serves as a glutathione precursor and substrate, replenishing hepatic glutathione and providing an alternative substrate for NAPQI conjugation, thereby limiting further hepatocyte injury. It is most effective when given early but has benefit even in later presentations.

• A. N-acetylcysteine does not inhibit CYP2E1; its protective effect comes from glutathione repletion and direct conjugation of NAPQI.
• C. N-acetylcysteine does not act as a direct chelator of NAPQI in the bloodstream; its mechanism is intracellular glutathione repletion and conjugation.
• D. Acetaminophen toxicity and its treatment are not mediated through renal tubular reabsorption competition.
• E. N-acetylcysteine does not act primarily by promoting hepatocyte mitosis; its protective effect is biochemical detoxification, not regeneration.

Coagulative necrosis, the typical pattern seen in myocardial infarction, is characterized by denaturation of structural proteins and enzymes that preserves the basic architecture (cell and tissue outlines) for several days even though the nucleus is lost and cytoplasm may appear more eosinophilic. At 24-72 hours after infarction, the dominant histologic feature is a dense neutrophilic infiltrate that begins removing the necrotic debris. This contrasts with liquefactive necrosis, in which enzymatic digestion by neutrophils completely dissolves the tissue architecture, a pattern not seen in the heart because cardiac tissue preserves its outline despite necrosis.

• A. Caseous necrosis shows amorphous granular debris without any preserved tissue architecture, typically surrounded by granulomas, not applicable to acute MI.
• B. Liquefactive necrosis involves complete dissolution of tissue architecture, which is not seen here since fiber outlines are preserved.
• C. Fat necrosis occurs in adipose tissue with calcium soap formation, unrelated to cardiac muscle infarction.
• E. Fibrinoid necrosis is seen in blood vessel walls in vasculitis or malignant hypertension, with fibrin deposition, not in infarcted myocardium.

Liquefactive necrosis occurs when hydrolytic enzymes released from infiltrating neutrophils (and in ischemic brain injury, from the brain's intrinsic lack of supportive stroma) digest the necrotic tissue, converting it into a soft, liquid viscous mass, commonly producing pus in bacterial abscesses. Brain abscesses and infarcts both characteristically liquefy because neuronal tissue has little structural collagen framework to resist enzymatic breakdown and is rich in hydrolytic enzymes released from dying leukocytes. This mechanism distinguishes liquefactive necrosis from coagulative necrosis, where protein denaturation predominates over enzymatic digestion, preserving tissue architecture.

• B. Fibrin and plasma protein deposition in vessel walls describes fibrinoid necrosis seen in vasculitis, unrelated to abscess formation.
• C. Lipid-laden macrophages producing a cheese-like appearance describes caseous necrosis in granulomatous disease, not a pyogenic abscess.
• D. Calcium soap (saponification) formation is characteristic of fat necrosis in adipose tissue, such as in acute pancreatitis, not brain abscess.
• E. Protein denaturation without significant enzymatic digestion describes coagulative necrosis, which preserves rather than dissolves architecture.

Caseous necrosis, the characteristic pattern seen in tuberculous granulomas, combines features of coagulative and liquefactive necrosis, producing a grossly cheese-like, friable, yellow-white appearance. Histologically it shows amorphous, structureless granular eosinophilic debris with complete loss of cellular outlines, unlike coagulative necrosis where architecture is preserved. This central necrotic zone is classically surrounded by a granulomatous rim of activated macrophages (epithelioid histiocytes), multinucleated giant cells, and lymphocytes, reflecting the cell-mediated immune response to Mycobacterium tuberculosis.

• A. Chalky-white calcium deposits in fat describe fat necrosis (saponification), typically seen in acute pancreatitis.
• B. Preserved cell outlines with loss of nuclei describes coagulative necrosis, as seen in myocardial infarction, not caseous necrosis.
• D. Liquid, pus-like tissue with neutrophils describes liquefactive necrosis, as in a pyogenic abscess, not a granuloma.
• E. Fibrinoid necrosis with bright pink material in a vessel wall is seen in vasculitis or malignant hypertension, not tuberculous granulomas.

In acute pancreatitis, released lipase enzymatically hydrolyzes peripancreatic and intra-abdominal fat, liberating free fatty acids. These fatty acids combine with circulating calcium ions to form insoluble calcium soaps, a process called saponification, which produces the grossly visible chalky white deposits. This calcium consumption lowers serum calcium levels, and the resulting hypocalcemia is a recognized poor prognostic marker (part of the Ranson criteria). This is distinct from dystrophic calcification, which involves calcification of already-dead tissue rather than active fatty acid-calcium binding.

• B. Coagulative necrosis sequestering calcium intracellularly is not the mechanism of fat necrosis-associated hypocalcemia.
• C. There is no autoimmune parathyroid process in acute pancreatitis; the hypocalcemia is due to peripheral calcium consumption, not decreased PTH.
• D. Acute pancreatitis does not primarily cause renal tubular injury or impaired vitamin D activation in this time frame.
• E. Metastatic calcification with calcium phosphate deposition in normal tissue occurs in hypercalcemic states, not pancreatitis.

Fibrinoid necrosis occurs when severely elevated blood pressure or immune-mediated vasculitis causes endothelial injury, allowing plasma proteins, including fibrin, to leak into and accumulate within the vessel wall. Histologically this produces a bright pink, amorphous, smudgy appearance on hematoxylin and eosin staining, often with associated wall necrosis and thrombosis. This lesion is characteristic of malignant hypertension and necrotizing vasculitides such as polyarteritis nodosa. It differs from coagulative necrosis of parenchymal cells, which involves denatured intracellular proteins rather than extravasated plasma proteins.

• A. This describes amyloidosis, which has a distinct apple-green birefringence under polarized light with Congo red stain, not fibrinoid necrosis.
• B. Fatty change describes intracellular lipid accumulation in cells like hepatocytes, not a vascular wall lesion from hypertension.
• C. Fibrinoid necrosis reflects extracellular plasma protein deposition, not denatured proteins within necrotic smooth muscle cells themselves.
• E. Dystrophic calcification of atherosclerotic vessels is a separate process not characterized by a bright pink amorphous appearance.

Dry gangrene results from chronic ischemic coagulative necrosis, typically from arterial occlusion in conditions like diabetic peripheral arterial disease, without superimposed bacterial infection. The tissue becomes dry, shrunken, and mummified with a clear line of demarcation, and the patient lacks systemic signs of infection such as fever or leukocytosis. In contrast, wet gangrene occurs when bacterial infection is superimposed on ischemic tissue, leading to liquefactive necrosis, foul odor, moist tissue breakdown, and systemic toxicity. This patient's dry, odorless, afebrile presentation with normal white blood cell count is consistent with dry rather than wet gangrene.

• B. There is no evidence of granuloma formation; this is a straightforward ischemic necrosis.
• C. Putrefactive, foul-smelling necrosis from anaerobic bacteria describes wet gangrene, inconsistent with this odorless, afebrile presentation.
• D. Fibrinoid necrosis is seen in vasculitis and malignant hypertension, not in ischemic dry gangrene of the toe.
• E. Liquefactive necrosis with neutrophilic digestion characterizes wet gangrene or abscess formation, which this patient does not have given the dry, non-odorous presentation.

The intrinsic (mitochondrial) apoptotic pathway is regulated by the balance between pro-apoptotic proteins such as BAX and BAK and anti-apoptotic proteins such as Bcl-2 and Bcl-xL. Cellular stress, including DNA damage from UV radiation, activates p53 and pro-apoptotic BH3-only proteins, shifting this balance toward BAX/BAK oligomerization, which permeabilizes the mitochondrial outer membrane and releases cytochrome c. Cytochrome c then binds Apaf-1 to form the apoptosome, activating caspase-9 and downstream executioner caspases. This pathway is triggered by internal cellular stress, unlike the extrinsic pathway, which is initiated by external death receptor ligation.

• A. Complement membrane attack complexes lyse plasma membranes in immune-mediated cell killing, not mitochondrial membranes in apoptosis.
• B. The death-inducing signaling complex is a feature of the extrinsic pathway, not the mitochondrial intrinsic pathway described here.
• C. Perforin-mediated pore formation is a cytotoxic T cell killing mechanism independent of the Bcl-2 family-regulated mitochondrial pathway.
• D. Fas-FasL binding initiates the extrinsic apoptotic pathway via death receptors, not mitochondrial outer membrane permeabilization.

Mast cell degranulation releases histamine, which binds H1 receptors on venular endothelial cells, causing actin-myosin-mediated contraction and formation of transient intercellular gaps. This increases vascular permeability predominantly in postcapillary venules, allowing protein-rich fluid to leak into the interstitium and produce the wheal and flare. This is the immediate transient response, distinct from the delayed prolonged leakage seen with direct injury. The effect is rapid (minutes) and reversible once histamine is degraded or receptors are blocked.

• A. Thrombosis is not the mechanism of acute wheal formation after a sting.
• B. Leukocyte-mediated injury typically affects capillaries and venules later in the inflammatory response, not within minutes.
• C. Angiogenesis is a feature of chronic inflammation and repair, occurring over days, not minutes.
• D. Direct toxic injury causes delayed, prolonged leakage from capillaries and venules, not the immediate histamine-driven response described here.

Cyclooxygenase (COX-1 and COX-2) converts arachidonic acid into prostaglandin G2 and then prostaglandin H2, the precursor for prostaglandins, prostacyclin, and thromboxane A2. NSAIDs such as this drug selectively inhibit COX without affecting the lipoxygenase pathway, so leukotriene synthesis from arachidonic acid continues unimpeded. This explains why NSAID use can paradoxically shunt substrate toward leukotriene production, worsening bronchospasm in aspirin-sensitive asthmatics. In contrast, corticosteroids inhibit phospholipase A2 and block both pathways.

• A. Phospholipase A2 acts upstream, releasing arachidonic acid from membrane phospholipids; inhibiting it would reduce both prostaglandins and leukotrienes.
• B. 5-lipoxygenase produces leukotrienes, not prostaglandin G2/H2, and this pathway is unaffected by the drug described.
• C. Thromboxane synthase acts downstream of COX to convert prostaglandin H2 into thromboxane A2, a later step than the one described.
• E. Leukotriene A4 hydrolase is part of the lipoxygenase pathway converting LTA4 to LTB4, unrelated to prostaglandin synthesis.

Leukocyte adhesion deficiency type 1 is caused by mutations in the gene encoding the beta-2 integrin subunit (CD18), which combines with CD11 to form LFA-1 and Mac-1. Without functional beta-2 integrins, neutrophils cannot achieve firm adhesion to ICAM-1 on endothelium or transmigrate into infected tissue, so pus (composed largely of neutrophils) cannot form despite marked neutrophilia in blood. Classic findings include delayed separation of the umbilical cord, recurrent skin and mucosal bacterial infections, and impaired wound healing. Diagnosis is confirmed by absent or reduced CD18 expression on flow cytometry.

• B. Complement C3 deficiency increases susceptibility to encapsulated bacterial infections but does not cause the specific CD18 defect described.
• C. Impaired fucosylation causes LAD type II, which presents with facial and growth abnormalities and is not defined by CD18 deficiency.
• D. Myeloperoxidase deficiency usually causes a mild or asymptomatic phagocytic defect, not recurrent severe infections with absent pus.
• E. NADPH oxidase defects cause chronic granulomatous disease with pus-forming granulomas and abscesses, not an absence of pus.

Leukotriene B4 is a potent chemoattractant produced by the 5-lipoxygenase pathway of arachidonic acid metabolism, acting alongside C5a, IL-8, and bacterial peptides (such as N-formylmethionine derivatives) to direct leukocyte chemotaxis along a chemical gradient toward the site of infection. Chemotactic agents bind specific G protein-coupled receptors on leukocytes, triggering actin polymerization and directional pseudopod formation. This is distinct from mediators like histamine that primarily affect vascular permeability rather than directed cell movement.

• A. Thromboxane A2 promotes platelet aggregation and vasoconstriction, not leukocyte chemotaxis.
• B. Bradykinin mediates pain and increases vascular permeability but does not function as a chemoattractant.
• C. Prostacyclin causes vasodilation and inhibits platelet aggregation; it does not direct leukocyte migration.
• D. Histamine increases vascular permeability via endothelial contraction but is not a chemoattractant for leukocytes.

Chronic granulomatous disease results from a defect in the phagocyte NADPH oxidase complex, most commonly an X-linked mutation in gp91phox, which prevents the conversion of molecular oxygen to superoxide during the respiratory burst. This impairs killing of catalase-positive organisms (such as S. aureus, Aspergillus, and Serratia marcescens) that can neutralize the small amount of hydrogen peroxide they generate themselves, while catalase-negative organisms (such as Streptococcus) are still killed using their own hydrogen peroxide via the patient's myeloperoxidase. The nitroblue tetrazolium test (and the newer dihydrorhodamine flow cytometry test) remains negative (no color change) because superoxide is not produced.

• A. Myeloperoxidase deficiency impairs hypochlorite formation but superoxide production and the respiratory burst remain largely intact, giving an abnormal but less severe phenotype.
• B. G6PD deficiency in neutrophils can impair the respiratory burst in rare severe cases, but it classically presents with hemolytic anemia and is not the typical cause of this syndrome.
• D. Superoxide dismutase deficiency is not a recognized cause of this clinical syndrome and would not abolish superoxide generation.
• E. Glutathione peroxidase deficiency is not associated with this clinical presentation or with failure of the respiratory burst test.

In granulomatous inflammation, CD4+ Th1 cells recognize persistent intracellular antigens (such as mycobacterial components) presented by macrophages and secrete interferon-gamma, which is the principal macrophage-activating cytokine. Interferon-gamma induces macrophages to transform into epithelioid histiocytes with abundant cytoplasm capable of secreting enzymes and cytokines, and multiple activated macrophages can fuse to form multinucleate giant cells. TNF-alpha, also produced by activated macrophages, helps recruit monocytes and maintain the granuloma, but it is interferon-gamma that drives the epithelioid transformation itself. This Th1-IFN-gamma-macrophage axis is central to granuloma formation in tuberculosis, sarcoidosis, and fungal infections.

• A. IL-4 is a Th2 cytokine associated with alternative macrophage activation and tissue repair/fibrosis, not epithelioid transformation in granulomas.
• B. IL-10 is an immunosuppressive cytokine that dampens macrophage activation, the opposite of what is needed for granuloma formation.
• C. TNF-alpha contributes to granuloma maintenance and recruitment but is not the primary driver of macrophage-to-epithelioid transformation.
• E. TGF-beta promotes fibrosis and immune regulation but does not drive the epithelioid transformation characteristic of granulomas.

The classical complement pathway is activated by antigen-antibody (IgG or IgM) immune complexes binding C1q, which activates C1r and C1s to cleave C4 and C2, forming the C3 convertase C4b2a. This convertase cleaves C3 into C3a (an anaphylatoxin) and C3b, amplifying the cascade and ultimately leading to formation of the membrane attack complex. In contrast, the alternative pathway is triggered by microbial surfaces and uses C3bBb as its C3 convertase, while the lectin pathway is triggered by mannose-binding lectin binding microbial carbohydrates and also generates C4b2a via MASP-mediated cleavage of C4 and C2.

• A. C3bBb3b is the C5 convertase of the alternative pathway, acting after C3 convertase formation, not the C3 convertase itself.
• B. The C5b-C9 complex is the membrane attack complex formed downstream of C3 convertase activity, not the convertase itself.
• C. C3bBb is the C3 convertase of the alternative pathway, triggered directly by microbial surfaces rather than immune complexes.
• E. Mannose-binding lectin-MASP complex initiates the lectin pathway by recognizing microbial carbohydrates, not immune complexes, and is not itself the convertase.

C1 esterase inhibitor normally restrains both the complement cascade and the kallikrein-kinin system. Its deficiency or dysfunction leads to unchecked activation of plasma kallikrein, which cleaves high-molecular-weight kininogen to generate excess bradykinin. Bradykinin increases vascular permeability and causes angioedema that does not respond to antihistamines, glucocorticoids, or epinephrine. This is why ACE inhibitors, which block bradykinin degradation, are contraindicated in these patients and can precipitate life-threatening attacks.

• B. IgE-mediated reactions produce urticaria and respond to standard anaphylaxis treatment, not seen here.
• C. Mast cell degranulation would typically respond to antihistamines and epinephrine, unlike this patient's episode.
• D. There is no history of opioid use, and opioids are not the mechanism in hereditary angioedema.
• E. Immune complex deposition causes serum sickness-type vasculitis, not isolated recurrent angioedema.

During the acute phase response, IL-6 released by macrophages stimulates hepatocytes to upregulate transcription of positive acute phase proteins such as CRP and fibrinogen while simultaneously downregulating albumin synthesis, making albumin a negative acute phase reactant. This reciprocal shift in hepatic protein output redirects amino acid resources toward proteins that support the inflammatory and coagulation response. The pattern of rising CRP and fibrinogen with falling albumin reflects this coordinated hepatic reprioritization rather than a problem with protein loss or liver failure.

• A. Isolated albuminuria does not explain the concurrent rise in fibrinogen and CRP.
• B. Capillary leak would lower CRP and fibrinogen too, which are rising here.
• C. Liver failure would impair synthesis of fibrinogen and CRP as well, which are both increasing.
• D. Dilution would lower all plasma proteins proportionally, not raise CRP and fibrinogen while albumin falls selectively.

Exogenous pyrogens such as bacterial lipopolysaccharide stimulate macrophages to release endogenous pyrogens IL-1 and TNF, which act on the hypothalamus to increase cyclooxygenase activity and raise prostaglandin E2 levels, resetting the hypothalamic thermoregulatory set point upward. Antipyretics such as acetaminophen and NSAIDs reduce fever by inhibiting cyclooxygenase, thereby decreasing hypothalamic PGE2 synthesis and allowing the set point to return toward normal. This mechanism explains why both acetaminophen and NSAIDs are effective antipyretics despite acetaminophen having minimal peripheral anti-inflammatory activity.

• B. Common antipyretics do not work by interfering with LPS-CD14 binding.
• C. Antipyretic action is centrally mediated through PGE2, not through peripheral nitric oxide-mediated vasodilation.
• D. Standard antipyretics do not act on Toll-like receptor signaling pathways.
• E. Antipyretics act downstream of IL-1 signaling by blocking prostaglandin synthesis, not by blocking IL-1 receptors directly.

Platelet-derived growth factor (PDGF), released by degranulating platelets and activated macrophages at the wound site, is a key chemoattractant and mitogen for fibroblasts and smooth muscle cells, driving their migration into the wound and proliferation to form granulation tissue. Together with TGF-beta and VEGF, PDGF promotes the formation of new capillaries and deposition of extracellular matrix, typically becoming prominent within the first week after injury. This granulation tissue later matures as collagen is remodeled and vascularity decreases, forming the fibrous scar.

• A. Granulocyte colony-stimulating factor stimulates neutrophil production and is not a primary driver of fibroblast recruitment in wound repair.
• B. Erythropoietin stimulates red blood cell production in the bone marrow and has no direct role in fibroblast recruitment at wound sites.
• C. Insulin-like growth factor binding proteins modulate IGF availability but are not the principal mediator of granulation tissue formation.
• E. Thrombopoietin stimulates platelet production in the bone marrow rather than fibroblast recruitment at the wound.

Vitamin C is a required cofactor for prolyl hydroxylase and lysyl hydroxylase, enzymes that hydroxylate proline and lysine residues on procollagen chains within the rough endoplasmic reticulum of fibroblasts. Hydroxylation is essential for forming stable hydrogen bonds between collagen triple helices; without it, collagen is underhydroxylated, cannot be properly secreted or cross-linked, and is structurally weak. This produces fragile blood vessels, causing perifollicular hemorrhages and gingival bleeding, and defective, poorly tensile wounds prone to dehiscence.

• A. Procollagen peptidase cleaves terminal propeptides extracellularly and does not require vitamin C.
• B. Lysyl oxidase is copper-dependent and cross-links collagen extracellularly; its deficiency is seen in copper deficiency, not scurvy.
• C. Matrix metalloproteinase-9 degrades extracellular matrix during remodeling and is not vitamin C-dependent.
• D. Collagenase degrades mature collagen and is not the enzyme affected in vitamin C deficiency.

Keloids result from excessive and disorganized collagen deposition during wound healing, with a higher proportion of type III collagen relative to normal scars and collagen bundles extending beyond the boundaries of the original wound. This exaggerated fibrotic response has a genetic predisposition and occurs more frequently in individuals with darker skin pigmentation, often at sites such as the earlobes, sternum, and shoulders. Unlike hypertrophic scars, which stay within the wound margins and tend to regress, keloids continue to grow and recur after excision.

• B. Granulation tissue with neutrophils and no collagen reflects early acute wound healing, not an established keloid.
• C. Dystrophic calcification in necrotic fat describes fat necrosis, not keloid scarring.
• D. Caseating necrosis with giant cells describes granulomatous inflammation such as tuberculosis, unrelated to keloid formation.
• E. This describes a normal mature scar, which is organized and confined to the wound, not a keloid.

Secondary intention healing involves large tissue defects that heal by granulation tissue formation and wound contraction. Fibroblasts differentiate into myofibroblasts, which express alpha-smooth muscle actin and contain contractile actin-myosin filaments that pull wound margins together, reducing the size of the defect. This process is most prominent in wounds healing by secondary intention and can take weeks. Excessive myofibroblast activity can lead to pathologic contractures.

• A. MMP-mediated collagen remodeling shapes the scar but does not produce the contractile force responsible for wound margin approximation.
• B. Granulation tissue formation provides the vascular bed for healing but endothelial proliferation itself does not pull wound edges together.
• D. Keratinocyte migration closes the epidermal surface but does not account for overall wound shrinkage.
• E. Lysyl oxidase cross-links collagen for tensile strength but does not cause contraction of the wound margins.

Exudates, as seen in infection or inflammation, result from increased vascular permeability due to inflammatory mediators that disrupt endothelial junctions, allowing protein and cells to leak into the extravascular space, producing fluid with high protein (greater than 2.9 g/dL or pleural/serum protein ratio greater than 0.5) and high LDH (pleural/serum LDH ratio greater than 0.6, per Light's criteria). Transudates, as in congestive heart failure, result from increased hydrostatic pressure with intact vascular permeability, producing protein-poor, cell-poor fluid. The pneumonia patient's fluid meets exudate criteria due to capillary leakiness from infection.

• A. Lymphatic obstruction causes a chylous or protein-variable effusion but is not the mechanism in bacterial pneumonia.
• B. Decreased capillary hydrostatic pressure would favor fluid resorption, not effusion formation, and does not explain an exudate.
• D. This mechanism describes transudate formation (as in the heart failure patient), not the protein-rich exudate seen in pneumonia.
• E. Hypoalbuminemia causes transudative effusions through decreased oncotic pressure, not the high-protein exudate described here.

In nephrotic syndrome, massive proteinuria leads to hypoalbuminemia, which decreases plasma oncotic pressure. This reduces the force holding fluid within the vasculature, allowing fluid to shift into the interstitial space according to Starling forces, producing generalized edema that is classically most apparent in low-pressure tissues like the periorbital area. Although secondary sodium retention from activation of the renin-angiotensin-aldosterone system also contributes in nephrotic syndrome, the primary initiating mechanism tested is the loss of oncotic pressure from hypoalbuminemia.

• A. Increased plasma osmolality would draw fluid into, not out of, the vascular space, which is the opposite of what occurs in nephrotic syndrome.
• B. Lymphatic obstruction by immune complexes is not a recognized mechanism of nephrotic edema; immune complexes affect the glomerular filtration barrier, not lymphatics.
• C. Increased hydrostatic pressure from sodium retention is a secondary contributor in nephrotic syndrome, not the primary mechanism being tested here.
• E. Increased vascular permeability from cytokines describes inflammatory or exudative edema, not the Starling force imbalance of nephrotic syndrome.

Surgical removal of axillary lymph nodes disrupts lymphatic drainage of the arm, leading to lymphedema. Because lymphatic vessels normally clear interstitial protein that escapes from capillaries, their obstruction causes accumulation of protein-rich fluid in the interstitium. This chronically stimulates fibroblast proliferation and collagen deposition, producing the non-pitting, indurated, thickened skin with a classic peau d'orange (orange-peel) appearance, as also seen in filarial lymphedema caused by Wuchereria bancrofti.

• B. There is no indication of enteropathy or systemic hypoalbuminemia in this patient; the edema is localized to the surgically affected limb.
• C. Arterial insufficiency would present with signs of ischemia such as pallor, coolness, and diminished pulses, not non-pitting protein-rich edema.
• D. There is no erythema or warmth to suggest an inflammatory process causing increased capillary permeability.
• E. Normal venous Doppler studies exclude venous obstruction as the cause of this patient's swelling.

Virchow triad describes the three major contributors to thrombus formation: stasis of blood flow (from immobilization and bed rest), endothelial injury (from surgical trauma to vessels), and a hypercoagulable state (from postoperative release of tissue factor and acute phase reactants). This patient has all three: immobility causing venous stasis, surgical trauma causing endothelial injury, and the postoperative state inducing hypercoagulability. Together these promote deep venous thrombosis, most commonly in the lower extremities.

• A. While endothelial injury contributes, increased vascular permeability is not a Virchow triad component; it relates to exudate formation.
• C. Arterial vasospasm and viscosity changes are not core components of Virchow triad for venous thrombosis.
• D. Oncotic pressure and lymphatic obstruction relate to edema formation, not thrombus formation.
• E. This patient has a venous, not arterial, thrombosis, so atherosclerotic plaque rupture and arterial hypertension are not relevant mechanisms.

Fat embolism syndrome classically occurs 24-72 hours after long bone fractures (especially femur) or orthopedic surgery, presenting with the triad of respiratory distress (from pulmonary capillary occlusion and inflammation), neurologic symptoms such as confusion (from cerebral microvascular occlusion), and a petechial rash over the upper body (from thrombocytopenia and dermal capillary occlusion by fat globules). Mild thrombocytopenia occurs because platelets adhere to the circulating fat globules. The delayed onset after fracture and the classic triad distinguish it from pulmonary thromboembolism.

• A. Sepsis-related ARDS would be expected to show evidence of infection such as fever and leukocytosis with a source, which is not described.
• C. Pulmonary thromboembolism typically presents with sudden dyspnea and pleuritic chest pain without the classic triad of petechiae and confusion seen here.
• D. Amniotic fluid embolism occurs peripartum in pregnant patients, not after long bone fracture in a male patient.
• E. While mild coagulopathy can occur in fat embolism syndrome, isolated DIC from trauma does not explain the full triad of respiratory distress, confusion, and petechiae in this clinical context.

Amniotic fluid embolism occurs when amniotic fluid, containing tissue factor, fetal cells, and other debris, enters the maternal circulation, typically during labor, delivery, or uterine trauma such as rupture. This triggers systemic activation of the coagulation cascade via the tissue factor (extrinsic) pathway, causing disseminated intravascular coagulation with consumption of platelets and clotting factors, evidenced by thrombocytopenia, prolonged PT/PTT, low fibrinogen, and elevated D-dimer. Simultaneously, amniotic fluid components trigger an anaphylactoid-like inflammatory response causing pulmonary vasospasm, right heart strain, and cardiorespiratory collapse.

• A. There is no indication of infection or sepsis in this patient; the mechanism is tissue factor exposure from amniotic fluid, not bacterial endotoxin.
• B. Uterine atony and dilutional coagulopathy from blood loss alone would not produce the acute cardiorespiratory collapse and the specific temporal association with amniotic fluid entry described here.
• D. Air embolism would present with a mill-wheel murmur and does not explain the coagulopathy seen in this patient.
• E. There is no mechanism by which fetal antigen exposure would cause acute autoimmune platelet destruction within minutes of delivery; this does not explain the full clinical picture of DIC.

Organs with a dual blood supply, such as the lung (pulmonary artery and bronchial arteries) and liver (hepatic artery and portal vein), develop hemorrhagic (red) infarcts because blood continues to seep into the necrotic area from the second circulation even after the primary vessel is occluded. Organs with a single (end-arterial) blood supply, such as the spleen, kidney, and heart, develop pale (anemic) infarcts because occlusion of the single supplying vessel prevents blood from re-entering the ischemic zone. Loose, spongy tissue architecture (as in lung) also favors hemorrhagic infarction. This distinction is tested by gross color and is a classic autopsy and imaging correlate.

• A. Elastic tissue content does not determine hemorrhagic versus pale infarct pattern.
• B. Metabolic rate influences susceptibility to ischemia, not infarct color.
• D. Macrophage density affects resolution timing, not the initial hemorrhagic appearance.
• E. Venous pressure differences are not the determinant of red versus pale infarction.

This patient has hypovolemic shock from gastrointestinal fluid losses, characterized by decreased preload (low wedge pressure reflecting low left ventricular filling), decreased cardiac output, and compensatory peripheral vasoconstriction producing high systemic vascular resistance. This pattern contrasts with cardiogenic shock, which has high wedge pressure (elevated filling pressure from pump failure), low cardiac output, and high SVR, and with early septic shock, which has low-to-normal wedge pressure, high cardiac output, and low SVR due to vasodilation. Cool, clammy skin reflects the vasoconstrictive response in hypovolemic and cardiogenic shock, differentiating them from the warm, flushed skin typical of early distributive (septic) shock.

• A. A normal wedge pressure with low SVR is inconsistent with volume-depleted hypovolemic shock.
• B. This combination of elevated filling pressure and high output does not correspond to any classic shock state.
• D. High cardiac output with low SVR describes the hyperdynamic phase of septic (distributive) shock, not hypovolemic shock.
• E. High wedge pressure indicates volume overload from pump failure, as in cardiogenic shock, not volume depletion.

In gram-negative septic shock, lipopolysaccharide (LPS, endotoxin) from the bacterial outer membrane binds CD14 and Toll-like receptor 4 (TLR4) on macrophages and endothelial cells, triggering release of TNF-alpha, IL-1, and IL-6. These cytokines cause widespread vasodilation (warm, flushed skin and low SVR), increased vascular permeability, and activation of coagulation that can progress to disseminated intravascular coagulation, explaining the thrombocytopenia and elevated D-dimer. This pathway is distinct from gram-positive toxic shock, which is mediated by superantigens that cross-link MHC class II and T-cell receptors independent of antigen specificity. Nitric oxide synthase upregulation downstream of TLR4 signaling is the principal mediator of the profound vasodilation seen in septic shock.

• A. Mast cell histamine release underlies anaphylactic shock, not septic shock from gram-negative bacteremia.
• C. Immune complex deposition causes vasculitis, not the acute vasodilatory response of septic shock.
• D. Superantigen activation describes toxic shock syndrome from gram-positive organisms (Staphylococcus aureus, Streptococcus pyogenes), not E. coli.
• E. Direct endothelial lysis is not the primary mechanism; endothelial dysfunction occurs secondary to cytokine-mediated activation.

Disseminated intravascular coagulation (DIC) is triggered here by amniotic fluid embolism and placental abruption, which release tissue factor into the maternal circulation and trigger systemic activation of the coagulation cascade. Widespread microthrombi consume platelets and clotting factors (thrombocytopenia, prolonged PT, low fibrinogen) while shearing red cells into schistocytes, and secondary fibrinolysis generates markedly elevated D-dimer. The combination of low platelets, low fibrinogen, prolonged PT, elevated D-dimer, and schistocytes on smear is the classic laboratory signature of DIC. Common triggers include obstetric catastrophes, sepsis, trauma, and malignancy, all of which expose blood to tissue factor or otherwise activate the extrinsic coagulation pathway.

• A. DIC involves primary activation of thrombin generation with secondary, not isolated, fibrinolysis.
• B. ADAMTS13 deficiency describes thrombotic thrombocytopenic purpura, which typically shows normal PT and fibrinogen.
• C. Amniotic fluid embolism causes DIC through tissue factor release, not direct marrow infiltration or suppression.
• D. Autoantibody-mediated platelet destruction (as in ITP) would not explain the prolonged PT, low fibrinogen, or schistocytes.

Huntington disease shows genetic anticipation, in which the CAG repeat expansion becomes larger and symptom onset occurs earlier in successive generations. This occurs because trinucleotide repeats are unstable during DNA replication, particularly during spermatogenesis, and paternal transmission is associated with greater expansion (in contrast to fragile X syndrome, where anticipation is more pronounced with maternal transmission). Larger repeat numbers correlate with earlier and more severe disease onset. Huntington disease is autosomal dominant with full penetrance, so X-inactivation and imprinting are not relevant to its inheritance pattern.

• A. X-inactivation applies to X-linked genes; HTT is located on chromosome 4, an autosome.
• C. Mitochondrial heteroplasmy applies to mitochondrial DNA inheritance, not nuclear trinucleotide repeat disorders.
• D. Huntington disease is not an imprinted disorder; both parental alleles are expressed equally.
• E. Somatic mosaicism from nondisjunction describes chromosomal aneuploidy, not trinucleotide repeat instability.

Mosaic Down syndrome arises when a zygote begins development with a normal 46-chromosome karyotype, but a mitotic nondisjunction event occurs in one cell during early postzygotic cleavage divisions, producing a mixture of trisomy 21 and normal diploid cell lines. Because only a fraction of the body's cells carry the extra chromosome 21, the phenotype is typically milder than in complete (nonmosaic) trisomy 21, consistent with this patient's attenuated features. In contrast, meiotic nondisjunction during oogenesis produces every cell in the body with trisomy 21 (full trisomy, the most common cause of Down syndrome, strongly associated with advanced maternal age). Robertsonian translocation causes a smaller subset of Down syndrome cases and does not produce mosaicism.

• A. A Robertsonian translocation produces a fused chromosome in all cells and is detected as an unbalanced translocation, not as mosaicism between trisomic and normal cell lines.
• B. Failure of cytokinesis in the first zygotic division would typically produce a tetraploid or non-viable outcome, not a mosaic trisomy 21/normal diploid pattern.
• C. Crossing over exchanges genetic material between homologs but does not create an extra copy of a chromosome.
• E. Meiosis I nondisjunction during oogenesis would result in trisomy 21 in all cells of the body, not a mosaic pattern.

In females, one X chromosome in each cell is randomly inactivated early in embryogenesis (Lyonization), and this pattern is then clonally maintained in all descendant cells. Carriers of X-linked recessive mutations such as dystrophin are typically asymptomatic because, on average, about half of their cells express the normal allele. However, due to the randomness of X-inactivation, some carriers have skewed inactivation favoring the normal allele (mild or no symptoms) while others have skewed inactivation favoring the mutant allele (more symptomatic, sometimes called manifesting carriers). This explains why carriers of the identical mutation can show a wide range of clinical severity and creatine kinase elevation.

• A. Dystrophin is located on the X chromosome and is not a known imprinted gene; imprinting of autosomal genes is not relevant here.
• B. Dystrophin is X-linked, and these patients are XX females; the Y chromosome and its methylation are not involved in this mechanism.
• C. CGG repeat expansion is characteristic of fragile X syndrome, not Duchenne muscular dystrophy, which results from deletions or point mutations in the dystrophin gene.
• D. Mitotic nondisjunction of the X chromosome would produce aneuploid cell lines (such as Turner mosaicism), not the variable expressivity seen with X-inactivation.

Mitochondrial DNA is inherited exclusively from the mother because the ovum contributes essentially all cytoplasmic organelles to the zygote, while sperm mitochondria are degraded after fertilization. During oogenesis and cell division, mitochondria replicate and segregate randomly, producing heteroplasmy, that is, differing ratios of mutant to wild-type mitochondrial DNA among tissues and offspring. Phenotype severity correlates with the mutant load exceeding a tissue-specific threshold, explaining why the son and daughter, despite inheriting the same mutation, have different clinical severity. This pattern is classic for mitochondrial myopathies such as those causing ragged red fibers.

• A. X-linked inheritance would show a distinct pattern of affected males and carrier females, not maternal-only transmission to all offspring.
• B. Autosomal dominant inheritance would show transmission from either parent and does not explain exclusive maternal transmission or ragged red fibers.
• C. Genomic imprinting affects specific nuclear genes, not the exclusive maternal transmission of the entire mitochondrial genome.
• D. Anticipation refers to worsening severity and earlier onset in successive generations due to repeat expansion, not variable mitochondrial mutant load.

Proto-oncogenes become oncogenes through gain-of-function mutations, such as point mutations, amplification, or translocation, and a single mutated allele is sufficient to drive transformation because the mutant protein acts dominantly, for example constitutively active RAS. Tumor suppressor genes normally restrain proliferation or promote apoptosis, and both alleles must be inactivated, the classic Knudson two-hit hypothesis, before their protective function is lost, as seen with RB and TP53. This one-hit versus two-hit distinction is the core conceptual difference between oncogenes and tumor suppressor genes at the cellular level. Germline two-hit tumor suppressor mutations explain hereditary cancer predisposition syndromes with early, bilateral, or multifocal tumors.

• A. Both gene classes can be mutated in germline or somatic cells; this is not the defining distinction between them.
• C. Both oncogenes and tumor suppressor genes can be altered by multiple mechanisms including point mutation, translocation, deletion, and amplification.
• D. This describes inheritance patterns in families, not the cellular mechanism of one-hit versus two-hit gene alteration, which can occur in sporadic as well as inherited cancers.
• E. Oncogenes and tumor suppressors are not defined by subcellular location; both classes include receptors, cytoplasmic proteins, and nuclear transcription factors.

This vignette describes Li-Fraumeni syndrome, caused by a germline mutation in TP53, which encodes the p53 tumor suppressor protein. In response to DNA damage, p53 is stabilized and acts as a transcription factor that upregulates p21, a cyclin-dependent kinase inhibitor that blocks cyclin-CDK complexes required for the G1-to-S transition, producing the G1/S checkpoint arrest. Loss of p53 function removes this checkpoint, allowing cells with damaged DNA to continue proliferating, which predisposes to early-onset, multiple primary cancers including osteosarcoma, breast cancer, and adrenocortical carcinoma, as seen in this family. This checkpoint failure is the central mechanism underlying Li-Fraumeni-associated tumorigenesis.

• A. p53 does not primarily act by inhibiting telomerase; telomerase regulation is a distinct mechanism from the G1/S checkpoint.
• C. This describes a separate mitotic entry control mechanism not directly regulated by p53.
• D. This describes the RB pathway, which normally acts downstream of and parallel to p53 signaling but is not the direct mechanism of p53-mediated G1 arrest.
• E. This describes a mitotic checkpoint mechanism unrelated to p53's G1/S checkpoint function.

Retinoblastoma follows the Knudson two-hit hypothesis: both alleles of the RB1 tumor suppressor gene must be inactivated for tumor formation. In hereditary cases, the first hit is inherited in the germline, present in every cell, so only one additional somatic mutation is needed in a retinal cell to inactivate the remaining allele. Because this second hit is a common, random somatic event, hereditary cases tend to be bilateral, multifocal, and present at a younger age, since multiple retinal cells have a head start toward malignancy. Sporadic cases require two independent somatic hits in the same cell, a much less likely event, explaining their later onset and typically unilateral, unifocal presentation.

• B. RB1 is a tumor suppressor gene inactivated by loss of function, not an oncogene activated by translocation.
• C. Inheriting two mutant alleles from both parents would require both parents to be carriers or affected, which is not the typical pattern; one germline hit plus one somatic hit is the standard mechanism.
• D. While epigenetic silencing can inactivate RB1 in some sporadic tumors, the earlier bilateral presentation in hereditary cases is explained by an inherited germline mutation, not de novo biallelic methylation.
• E. Mismatch repair defects cause Lynch syndrome and other cancers with microsatellite instability, not the classic two-hit RB1 mechanism in retinoblastoma.

High-risk HPV types, such as 16 and 18, encode the E6 and E7 oncoproteins, which inactivate tumor suppressor proteins without mutating their genes. E6 protein binds p53 and promotes its degradation via the ubiquitin-proteasome pathway, while E7 protein binds retinoblastoma protein and displaces E2F transcription factors, functionally mimicking RB phosphorylation and driving cells into S phase. This dual inactivation of the two major cell cycle checkpoints explains the normal gene sequences but low functional protein levels, and underlies the oncogenic potential of high-risk HPV in cervical, anal, and oropharyngeal carcinoma. This mechanism is the basis for HPV vaccination strategies targeting E6/E7-expressing high-risk strains.

• A. HPV oncoproteins act post-translationally on existing protein, not through insertional mutagenesis of the TP53 gene, and the gene sequence here is normal.
• B. Promoter hypermethylation is not the primary HPV oncogenic mechanism; E6 and E7 directly bind and inactivate the tumor suppressor proteins.
• D. HPV does not use an RNA interference mechanism to degrade RB1 or TP53 mRNA; E6/E7 act at the protein level.
• E. L1 is the HPV capsid protein involved in viral assembly and is the target of HPV vaccines, not a mediator of p53 or RB inactivation.

This clinical and histologic picture, a jaw mass in a child from an EBV-endemic region with a starry sky pattern of sheets of lymphoid cells interspersed with macrophages, is classic for Burkitt lymphoma. The defining cytogenetic abnormality is t(8;14), which relocates the c-myc proto-oncogene on chromosome 8 next to the immunoglobulin heavy chain enhancer on chromosome 14, causing constitutive overexpression of c-myc and driving uncontrolled proliferation. EBV is strongly associated with the endemic African form of Burkitt lymphoma, infecting B cells and contributing to the genetic instability that favors this translocation. The starry sky appearance reflects the high proliferation rate with numerous apoptotic cells being cleared by benign macrophages.

• A. t(11;14) involving cyclin D1 is characteristic of mantle cell lymphoma, not Burkitt lymphoma.
• B. t(14;18) involving BCL2 is characteristic of follicular lymphoma, which presents differently and lacks the starry sky pattern.
• D. t(15;17) is characteristic of acute promyelocytic leukemia, a myeloid, not lymphoid, malignancy.
• E. t(9;22), the Philadelphia chromosome, is characteristic of chronic myeloid leukemia, not Burkitt lymphoma.

Aflatoxin B1 is produced by Aspergillus flavus and Aspergillus parasiticus, molds that contaminate improperly stored grains, corn, and peanuts in warm, humid climates. The liver metabolizes aflatoxin B1 via cytochrome P-450 into a reactive epoxide that forms DNA adducts, producing a characteristic G-to-T transversion mutation at codon 249 of TP53, resulting in an arginine-to-serine substitution. This specific p53 mutation is a molecular signature strongly linked to aflatoxin-induced hepatocellular carcinoma, and its carcinogenic effect is markedly synergistic with chronic hepatitis B infection, though it can occur independently. This patient's negative viral serologies and codon 249 mutation point specifically toward aflatoxin exposure as the causative carcinogen.

• B. Arsenic exposure is associated with angiosarcoma of the liver and skin and lung cancers, not this specific aflatoxin-associated p53 mutation.
• C. Thorotrast, a historical radiographic contrast agent, is associated with angiosarcoma and cholangiocarcinoma of the liver due to its radioactivity, not this specific point mutation.
• D. Vinyl chloride exposure is classically associated with hepatic angiosarcoma, not hepatocellular carcinoma with this specific p53 mutation.
• E. Nitrosamines are associated with gastric and esophageal cancers, not this specific codon 249 TP53 mutation.

CA 19-9 is elevated in most pancreatic adenocarcinomas and is useful for monitoring response to treatment and detecting recurrence after a baseline level has been established, because rising levels correlate with tumor burden in a patient already known to have the disease. It lacks sufficient sensitivity and specificity for screening asymptomatic individuals, even relatives, since it is also elevated in benign biliary obstruction and pancreatitis. AFP and CA-125 are markers for hepatocellular carcinoma/germ cell tumors and ovarian cancer, respectively, not pancreatic cancer. Tumor markers in general are not validated as population screening tools due to low positive predictive value in low-prevalence populations.

• B. No tumor marker, including CA 19-9, is recommended for general population cancer screening.
• C. CA-125 is used for ovarian cancer monitoring, not pancreatic cancer.
• D. AFP is a marker for hepatocellular carcinoma and yolk sac tumors, not pancreatic adenocarcinoma.
• E. CA 19-9 has poor specificity and sensitivity for population screening, even in relatives of a patient with pancreatic cancer.

Cancer cachexia results from systemic release of pro-inflammatory cytokines, most notably tumor necrosis factor-alpha (TNF-alpha, originally named cachectin), secreted by tumor cells and host macrophages in response to the tumor. TNF-alpha promotes muscle proteolysis through the ubiquitin-proteasome pathway, suppresses appetite centrally, and increases lipolysis in adipose tissue, producing the combined loss of muscle and fat mass characteristic of cachexia independent of caloric intake. Interleukin-6 and interferon-gamma contribute similarly, but TNF-alpha is the prototypical mediator historically linked to this syndrome. This mechanism explains why cachexia persists despite adequate nutritional intake, differentiating it from simple starvation.

• A. GM-CSF stimulates myeloid cell production and is not a principal mediator of the cachexia syndrome.
• B. Interleukin-2 is primarily involved in T-cell proliferation and is used therapeutically in some cancers, not a primary mediator of cachexia.
• C. Transforming growth factor-beta is involved in fibrosis and immune suppression, not the principal mediator of cachexia.
• E. Interleukin-4 promotes Th2 differentiation and IgE class switching, unrelated to cachexia pathogenesis.

Local invasion through the basement membrane requires loss of E-cadherin, a transmembrane glycoprotein that normally maintains cell-cell adhesion in epithelium; its downregulation (often through promoter hypermethylation or transcriptional repression by factors such as Snail and Slug) releases tumor cells from their neighbors and from beta-catenin-mediated signaling control. Concurrently, tumor and stromal cells upregulate matrix metalloproteinases, particularly MMP-2 and MMP-9 (type IV collagenases), which degrade the type IV collagen network of the basement membrane, creating a path for invasion. Together, loss of adhesion and proteolytic degradation of the basement membrane constitute the first steps of the invasion-metastasis cascade, preceding intravasation into blood or lymphatic vessels. This combination is a well-established feature distinguishing invasive carcinoma from carcinoma in situ.

• A. Increased E-cadherin and decreased MMP activity would favor cell adhesion and basement membrane integrity, opposing invasion.
• C. Desmoplakin is a component of desmosomes, not the primary adhesion molecule implicated in epithelial-mesenchymal transition for invasion.
• D. Integrins mediate cell-matrix attachment and are not characteristically decreased in a way that promotes basement membrane invasion; increased collagen synthesis would not facilitate degradation of the membrane.
• E. Selectins mediate leukocyte rolling and adhesion to endothelium, a later step in metastasis (intravascular arrest), not basement membrane invasion.

Malignant neoplasms are histologically distinguished from benign ones by features reflecting loss of normal growth control and differentiation: pleomorphism (variation in cell and nuclear size/shape), increased and atypical mitotic figures, nuclear changes such as irregular borders and chromatin clearing, loss of normal tissue architecture, and most definitively, invasion through the capsule or basement membrane into surrounding tissue. In thyroid pathology specifically, capsular and/or vascular invasion is the key criterion separating follicular carcinoma from follicular adenoma, since both can otherwise appear cytologically similar. The combination of marked pleomorphism, high mitotic rate, and unequivocal invasion beyond the capsule in this vignette confirms malignancy.

• A. Follicular carcinomas are specifically defined by capsular and/or vascular invasion, which is described in this vignette.
• B. A fibrous capsule alone is a nonspecific finding present in both adenomas and carcinomas; invasion through it, not its mere presence, indicates malignancy.
• C. Nuclear atypia combined with invasive growth beyond the capsule is sufficient evidence of malignancy; architectural distortion is present here as well.
• D. Preserved polarity does not override the presence of marked pleomorphism, high mitotic activity, and capsular invasion, all of which indicate malignancy.

This patient has AL (primary) amyloidosis, in which clonal plasma cells, as in multiple myeloma, produce excess monoclonal immunoglobulin light chains that misfold into insoluble beta-pleated sheet fibrils and deposit extracellularly in tissues including kidney, heart, and tongue, producing macroglossia and nephrotic-range proteinuria. Congo red staining binds the beta-pleated sheet structure and produces characteristic apple-green birefringence under polarized light, the classic diagnostic feature of all amyloid subtypes regardless of the precursor protein. Electron microscopy classically shows non-branching fibrils arranged in a haphazard, random pattern, which is also typical across amyloid types but confirms the diagnosis of amyloidosis. Immunohistochemistry or mass spectrometry can further confirm light chain origin to distinguish AL amyloidosis from other subtypes such as AA amyloidosis.

• A. Transthyretin is the precursor protein in familial and senile systemic (wild-type) amyloidosis, not the subtype associated with multiple myeloma.
• B. Amyloid precursor protein fragments (beta-amyloid) deposit in cerebral vessels and plaques in Alzheimer disease, unrelated to multiple myeloma.
• D. Serum amyloid A is the precursor in AA (secondary) amyloidosis, associated with chronic inflammatory conditions such as rheumatoid arthritis or chronic infections, not plasma cell dyscrasias.
• E. Beta-2 microglobulin accumulates in dialysis-related amyloidosis in patients with chronic kidney disease on long-term hemodialysis, not multiple myeloma.